Literature DB >> 1628095

Intra-arterial temazepam.

M Adiseshiah, D A Jones, J M Round.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1628095      PMCID： PMC1881958          DOI： 10.1136/bmj.304.6842.1630-a

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  50 years on: the crush syndrome.

Authors:  E G Bywaters
Journal:  BMJ       Date:  1990 Dec 22-29

Review 2.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 3.  Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis.

Authors:  O S Better; J H Stein
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245
  3 in total
  6 in total

1.  Misuse of temazepam.

Authors:  A P Launchbury; J Drake; H Seager
Journal:  BMJ       Date:  1992-07-25

2.  Misuse of temazepam.

Authors:  R Fox; N J Beeching; C Morrison; S Ruben; T Garvey
Journal:  BMJ       Date:  1992-07-25

3.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

4.  Death from pulmonary microembolisation after intravenous injection of temazepam.

Authors:  E J Vella; C W Edwards
Journal:  BMJ       Date:  1993-07-03

5.  Limb ischaemia after intra-arterial injection of Temazepam gel: histology of nine cases.

Authors:  T J Dodd; R N Scott; K R Woodburn; J J Going
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

6.  A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Douglas Y Shapiro; Sandra D Comer
Journal:  Addiction       Date:  2013-03-13       Impact factor: 6.526
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.